Health Tech Capitol | Biological Industries USA Adds Vitronectin XF™ to its Stem Cell Portfolio Through Agreement with Primorigen Biosciences, Inc.
16337
post-template-default,single,single-post,postid-16337,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Biological Industries USA Adds Vitronectin XF™ to its Stem Cell Portfolio Through Agreement with Primorigen Biosciences, Inc.

06 Jun Biological Industries USA Adds Vitronectin XF™ to its Stem Cell Portfolio Through Agreement with Primorigen Biosciences, Inc.

Posted at 15:01h in Uncategorized by
0 Likes

Biological Industries USA (BI-USA), a division of Biological Industries Beit Haemek Israel (BI), and Madison-based Primorigen Biosciences, Inc. announce a strategic partnership for non-exclusive worldwide distribution of Primorigen’s proprietary Vitronectin XF™ protein matrix for stem cell culture.

“Primorigen and Vitronectin XF™ are an excellent fit with BI-USA’s strategic goal of providing defined and reliable solutions to further advance stem cell research, cell therapy development, and drug discovery,” commented Daniel Haus, PhD, Scientific Affairs Manager at BI-USA.

Read more at BusinessWire

No Comments

Sorry, the comment form is closed at this time.